Post hoc analysis of 552 faricimab-treated nAMD participants from two RCTs: fluid resolution through week 12 was associated with greater likelihood of every-16-week vs every-8-week dosing at week 20/24 (OR 1.99) and week 112 (OR 1.76; 478 analysed).
Secondary analysisn = 552
Pitcher et al. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration